"Driving Innovation Across Healthcare, Agriculture, and Environmental Science, Microbiome Sequencing Unlocks the Power of Microbial DNA to Enable Personalized Medicine, Sustainable Farming, and Ecosystem...
"Driving Innovation Across Healthcare, Agriculture, and Environmental Science, Microbiome Sequencing Unlocks the Power of Microbial DNA to Enable Personalized Medicine, Sustainable Farming, and Ecosystem...
BANGALORE, India, Aug. 4, 2025 /PRNewswire/ --
What is the Market Size of IoT Automation and Control Systems Market?
Year
Market Size (USD Million)
2024
USD 25460 Million
2031
USD 65040...
BANGALORE, India, Aug. 4, 2025 /PRNewswire/ --
What is the Market Size of IoT Automation and Control Systems Market?
Year
Market Size (USD Million)
2024
USD 25460 Million
2031
USD 65040...
Dr Jill's MDLifespan Mold Protocol is the First Clinically Proven Therapeutic Plasma Exchange Detox to Remove up to 90% of Mold Toxins
DENVER, Aug. 4,...
New Jersey shop manager recognized for expertise, leadership, and enthusiasm for the transportation industry
WALL, N.J., Aug. 4, 2025 /PRNewswire/ -- Student Transportation of America...
ACCRA, Ghana, Aug. 4, 2025 /PRNewswire/ -- GTI Holding, a leading African investment conglomerate based in Ghana, has announced strong momentum across its key...
FRANKLIN LAKES, N.J., Aug. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to...
AUCKLAND, New Zealand, Aug. 4, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive...
AUCKLAND, New Zealand, Aug. 4, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive...
AUCKLAND, New Zealand, Aug. 4, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive...
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States.
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.